SEC Company Response from Sarepta Therapeutics, Inc. (SRPT) (CIK 0000873303) (SRPT) — Apr 15, 2020
Sarepta Therapeutics, Inc. (SRPT) (CIK 0000873303)
Date: April 15, 2020 · CIK: 0000873303 · Accession: 0001193125-20-107782
AI Filing Summary & Sentiment
File numbers found in text: 001-14895
Referenced dates: April 13, 2020
Letter
Re: Sarepta Therapeutics, Inc.
ROPES & GRAY LLP
PRUDENTIAL TOWER
800 BOYLSTON STREET
BOSTON, MA 02199-3600
WWW.ROPESGRAY.COM
April 15, 2020
BY EDGAR TRANSMISSION
Preliminary Proxy Statement on Schedule 14A
Filed on April 8, 2020 by Sarepta Therapeutics, Inc.
SEC Comment Letter dated April 13, 2020
File No. 001-14895
Ladies and Gentlemen:
On behalf of Sarepta Therapeutics, Inc. (the “Company”), we are providing the Company’s response to the comment in the letter, dated April 13, 2020 (the “Comment Letter”), of the staff (the “Staff”) of the Securities and Exchange Commission with respect to the Company’s above-referenced preliminary proxy statement on Schedule 14A filed on April 8, 2020.
The Staff’s comment, as reflected in the Comment Letter, is reproduced in italics in this letter, and the response of the Company is shown below the comment.
Preliminary Proxy Statement on Schedule 14A
Restated Certificate Amendment (Proposal 3), page 19
1. Please revise the proxy statement to indicate whether you currently have any plans, arrangements or understandings, written or oral, to issue any of the authorized but unissued shares that would become available as a result of the amendment to the Restated Certificate.
In response to the Staff’s comment, the Company will add the following disclosure under the heading “Restated Certificate Amendment (Proposal 3)—Purpose and Effect of the Proposal” in its definitive proxy statement on Schedule 14A: “Other than with respect to Proposal 4, the Company has no definitive plan, arrangement, or understanding to issue the additional shares of common stock.”
If you have any questions or comments about this letter or need any further information, please direct any communications to the undersigned at (617) 951-7921 or paul.kinsella@ropesgray.com or to my colleague, Raymond Grant at (617) 235-4668 or raymond.grant@ropesgray.com.
Respectfully Submitted,
/s/ Paul M. Kinsella
Show Raw Text
CORRESP 1 filename1.htm CORRESP ROPES & GRAY LLP PRUDENTIAL TOWER 800 BOYLSTON STREET BOSTON, MA 02199-3600 WWW.ROPESGRAY.COM April 15, 2020 BY EDGAR TRANSMISSION Re: Sarepta Therapeutics, Inc. Preliminary Proxy Statement on Schedule 14A Filed on April 8, 2020 by Sarepta Therapeutics, Inc. SEC Comment Letter dated April 13, 2020 File No. 001-14895 Ladies and Gentlemen: On behalf of Sarepta Therapeutics, Inc. (the “Company”), we are providing the Company’s response to the comment in the letter, dated April 13, 2020 (the “Comment Letter”), of the staff (the “Staff”) of the Securities and Exchange Commission with respect to the Company’s above-referenced preliminary proxy statement on Schedule 14A filed on April 8, 2020. The Staff’s comment, as reflected in the Comment Letter, is reproduced in italics in this letter, and the response of the Company is shown below the comment. Preliminary Proxy Statement on Schedule 14A Restated Certificate Amendment (Proposal 3), page 19 1. Please revise the proxy statement to indicate whether you currently have any plans, arrangements or understandings, written or oral, to issue any of the authorized but unissued shares that would become available as a result of the amendment to the Restated Certificate. In response to the Staff’s comment, the Company will add the following disclosure under the heading “Restated Certificate Amendment (Proposal 3)—Purpose and Effect of the Proposal” in its definitive proxy statement on Schedule 14A: “Other than with respect to Proposal 4, the Company has no definitive plan, arrangement, or understanding to issue the additional shares of common stock.” If you have any questions or comments about this letter or need any further information, please direct any communications to the undersigned at (617) 951-7921 or paul.kinsella@ropesgray.com or to my colleague, Raymond Grant at (617) 235-4668 or raymond.grant@ropesgray.com. Respectfully Submitted, /s/ Paul M. Kinsella Paul M. Kinsella